

A CRISPR-Cas9 screen to identify genetic modifiers of APP/BACE-1 interactions

<https://www.neurodegenerationresearch.eu/survey/a-crispr-cas9-screen-to-identify-genetic-modifiers-of-app-bace-1-interactions/>

Principal Investigators

ROY, SUBHOJIT

Institution

UNIVERSITY OF WISCONSIN-MADISON

Contact information of lead PI

Country

USA

Title of project or programme

A CRISPR-Cas9 screen to identify genetic modifiers of APP/BACE-1 interactions

Source of funding information

NIH (NIA)

Total sum awarded (Euro)

374339.4495

Start date of award

15/07/2016

Total duration of award in years

1

Keywords

Acquired Cognitive Impairment... Aging... Alzheimer's Disease... Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD)... Biotechnology... Brain Disorders... Dementia... Genetics... Human Genome... Neurodegenerative... Neurosciences

Research Abstract

? DESCRIPTION (provided by applicant): The overall goal of this proposal is to discover molecules along trafficking pathways leading to the convergence of two key proteins in Alzheimer's disease (AD) pathogenesis – Amyloid Precursor Protein (APP) and ?-site APP-cleaving enzyme-1 (BACE-1). This convergence, and consequent enzymatic ?-cleavage of

APP, is the rate-limiting step of amyloid beta (A β) production – a pathological hallmark of AD brains and a prevailing focus in AD research. Visualizing APP/BACE-1 trafficking in hippocampal neurons, we recently found that after synthesis, APP and BACE-1 are sorted into distinct vesicles, with BACE-1 selectively routed into recycling endosomes. At steady state, APP and BACE-1 convergence is a low-frequency event – producing A β at basal levels (Das et al., Neuron 2013; PMID: 23931995). Following up on these studies, we reasoned that ascertaining molecular pathways leading up-to this seminal convergence event would allow: 1) identification of the repertoire of trafficking pathways by which APP and BACE-1 meet to initiate the amyloidogenic cascade; and 2) discovery of novel “druggable targets” that can be manipulated to diminish APP/BACE-1 convergence and A β production. Towards this we developed an in-cellulo Optical assay to visualize Convergence of APP and BACE-1 (OptiCAB). Based on fluorescence complementation, this assay reports APP/BACE-1 interactions as a simple on/off readout, correlates with APP β -cleavage, and is suitable for large-scale analyses. Combining this assay with a newly-developed powerful genome-scale screen using CRISPR-Cas9 knockout (GeCKO) library (collaboration with Feng Zhang, MIT), our goal is to discover genes involved in ‘trafficking-related’ upstream pathways that eventually lead to APP/BACE-1 convergence and A β production. Notably, CRISPR-Cas9- based screens are not limited by incomplete protein depletion and confounding off-target effects that have historically limited the utility of RNAi. Secondary validation of ‘hits’ (i.e. genes that attenuate APP/BACE-1 interactions) will be done in human induced pluripotent stem cells (iPSC’s); where APP-cleavage products will be analyzed after relevant CRISPR-knockout. Our aims are: Aim #1: Discover pathways leading to APP and BACE-1 convergence using OptiCAB and GeCKO; and Aim #2: Validate ‘hits’ from Aim 1 in human neuronally-differentiated iPSCs. Our experiments will not only provide insights into the physiologic “amyloid-pathway” in humans, but may also offer new targets for AD. Finally, note that our focus on the repertoire of trafficking pathways leading up-t APP/BACE-1 approximation stems from our own live-imaging studies; and is different from the current narrow focus on enzymatic activity of the secretases.

Further information available at:

Types:

Investments < €500k

Member States:

United States of America

Diseases:

N/A

Years:

2016

Database Categories:

N/A

Database Tags:

N/A